Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Core Insights - Lexicon Pharmaceuticals, Inc. announced the presentation of clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025) [1] - The data comes from the SOTA-P-CARDIA trial, which focused on patients with heart failure with preserved ejection fraction (HFpEF) [2] - Craig Granowitz, M.D., Ph.D., highlighted that the new data supports sotagliflozin's differentiated benefits compared to SGLT2 inhibitors [3] Sotagliflozin Overview - Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1, which are involved in glucose regulation [4] - The drug has been studied in various patient populations, including approximately 20,000 patients across heart failure, diabetes, and chronic kidney disease [4] - Sotagliflozin is also under investigation for hypertrophic cardiomyopathy (HCM) [4] Company Background - Lexicon Pharmaceuticals aims to pioneer medicines that transform patients' lives through its Genome5000™ program, which has identified over 100 protein targets with therapeutic potential [5] - The company has a pipeline of drug candidates in various stages of development, focusing on neuropathic pain, HCM, metabolism, and other indications [5]